
Philippe Chavatte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2212911/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. PLoS ONE, 2021, 16, e0257281.	1.1	5
2	GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis. Cellular and Molecular Immunology, 2020, 17, 1272-1274.	4.8	4
3	Development of novel oxazolo[5,4-d]pyrimidines as competitive CB2 neutral antagonists based on scaffold hopping. European Journal of Medicinal Chemistry, 2018, 146, 68-78.	2.6	16
4	Importance of the second extracellular loop for melatonin MT ₁ receptor function and absence of melatonin binding in GPR50. British Journal of Pharmacology, 2018, 175, 3281-3297.	2.7	23
5	Chlorinated and brominated bisphenol A derivatives: Synthesis, characterization and determination in water samples. Chemosphere, 2018, 213, 434-442.	4.2	18
6	Toward the Discovery of a Novel Class of YAP–TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP–TEAD Protein–Protein Interface. Cancers, 2018, 10, 140.	1.7	36
7	Development and validation of a reversedâ€phase HPLC method for the quantification of paclitaxel in different PLGA nanocarriers. Electrophoresis, 2017, 38, 2536-2541.	1.3	8
8	Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and <i>N</i> -Acylethanolamine Acid Amidase Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 4-46.	2.9	89
9	Design, synthesis and biological evaluation of potent FAAH inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2701-2705.	1.0	14
10	Exploring chiral separation of 3-carboxamido-5-aryl isoxazole derivatives by supercritical fluid chromatography on amylose and cellulose tris dimethyl- and chloromethyl phenylcarbamate polysaccharide based stationary phases. Journal of Chromatography A, 2016, 1467, 473-481.	1.8	7
11	Docking study: PPARs interaction with the selected alternative plasticizers to di(2-ethylhexyl) phthalate. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 31, 1-8.	2.5	14
12	Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines. European Journal of Medicinal Chemistry, 2015, 106, 15-25.	2.6	3
13	Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis. ACS Medicinal Chemistry Letters, 2015, 6, 198-203.	1.3	23
14	Relationships between Th1 or Th2 iNKT Cell Activity and Structures of CD1d-Antigen Complexes: Meta-analysis of CD1d-Glycolipids Dynamics Simulations. PLoS Computational Biology, 2014, 10, e1003902.	1.5	5
15	NMR studies of interactions of new CB2 cannabinoid receptor ligands with cyclodextrins hosts. Correlation with micellar electrokinetic chromatography and reversed phase high performance liquid chromatography. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2014, 78, 265-274.	0.9	0
16	Switching cannabinoid response from CB2 agonists to FAAH inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1322-1326.	1.0	12
17	Preclinical Studies of a Specific PPARγ Modulator in the Control of Skin Inflammation. Journal of Investigative Dermatology, 2014, 134, 1001-1011.	0.3	44
18	Enantioseparation of pyroglutamide derivatives on polysaccharide based chiral stationary phases by high-performance liquid chromatography and supercritical fluid chromatography: A comparative study. Journal of Chromatography A, 2014, 1363, 257-269.	1.8	19

#	Article	IF	CITATIONS
19	Switching Invariant Natural Killer T (iNKT) Cell Response from Anticancerous to Anti-Inflammatory Effect: Molecular Bases. Journal of Medicinal Chemistry, 2014, 57, 5489-5508.	2.9	62
20	Therapeutical Potential of CB ₂ Receptors in Immune-Related Diseases. Current Molecular Pharmacology, 2014, 6, 183-203.	0.7	27
21	3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis. Bioorganic and Medicinal Chemistry, 2013, 21, 5383-5394.	1.4	36
22	Virtual Screening of CB ₂ Receptor Agonists from Bayesian Network and Highâ€Throughput Docking: Structural Insights into Agonistâ€Modulated GPCR Features. Chemical Biology and Drug Design, 2013, 81, 442-454.	1.5	19
23	Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents. Current Medicinal Chemistry, 2012, 19, 3457-3474.	1.2	33
24	4-Oxo-1,4-dihydropyridines as Selective CB ₂ Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis. Journal of Medicinal Chemistry, 2012, 55, 8948-8952.	2.9	21
25	Synthesis and Structure–Activity Relationships of (Aryloxy)quinazoline Ureas as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 1189-1204.	2.9	55
26	Scaffold hopping strategy toward original pyrazolines as selective CB2 receptor ligands. European Journal of Medicinal Chemistry, 2012, 58, 396-404.	2.6	11
27	Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators. Journal of Medicinal Chemistry, 2012, 55, 4027-4061.	2.9	160
28	Microwave-mediated synthesis and manipulation of a 2-substituted-5-aminooxazole-4-carbonitrile library. Tetrahedron Letters, 2012, 53, 1656-1659.	0.7	18
29	Preclinical Evaluation of Intestinal Anti-Inflammatory/Analgesic Properties and Phase I Clinical Trial of a New PPAR Agonist Ged-0507-34-Levo. Gastroenterology, 2011, 140, S-515.	0.6	2
30	Potent Farnesyltransferase Inhibitors with 1,4-Diazepane Scaffolds as Novel Destabilizing Microtubule Agents in Hormone-Resistant Prostate Cancer. Journal of Medicinal Chemistry, 2011, 54, 1178-1190.	2.9	16
31	Genetic polymorphism of CYP4A11 and CYP4A22 genes and in silico insights from comparative 3D modelling in a French population. Gene, 2011, 487, 10-20.	1.0	15
32	Antioxydant activity of β-carboline derivatives in the LDL oxidation model. European Journal of Medicinal Chemistry, 2011, 46, 2575-2585.	2.6	17
33	New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis. Bioorganic and Medicinal Chemistry, 2011, 19, 3777-3786.	1.4	38
34	Homology Modeling of 5-HT2C Receptors. , 2011, , 97-127.		0
35	Synthesis of 2,3 and 4,5-Dihydro-hydroxy-isoxazoles and Isoxazoles Under Different pH Conditions. Letters in Organic Chemistry, 2010, 7, 32-38.	0.2	10
36	Conformational analysis of tripeptide Ac-Lys-Pro-Val-NH2, COOH-terminal sequence of alpha-MSH. Journal of Pharmacy and Pharmacology, 2010, 53, 949-953.	1.2	3

#	Article	IF	CITATIONS
37	Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT1 melatoninergic ligands. Bioorganic and Medicinal Chemistry, 2010, 18, 3426-3436.	1.4	21
38	Novel structural insights for drug design of selective 5-HT2C inverse agonists from a ligand-biased receptor model. European Journal of Medicinal Chemistry, 2010, 45, 5086-5099.	2.6	8
39	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8772-8777.	3.3	183
40	4-Oxo-1,4-dihydropyridines as Selective CB ₂ Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series. Journal of Medicinal Chemistry, 2010, 53, 7918-7931.	2.9	30
41	Structural Insight into PPARγ Ligands Binding. Current Medicinal Chemistry, 2009, 16, 1768-1789.	1.2	46
42	2,6-Diphenylthiazolo[3,2-b][1,2,4]triazoles as telomeric G-quadruplex stabilizers. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3434-3438.	1.0	25
43	Homology modeling of MT1 and MT2 receptors. European Journal of Medicinal Chemistry, 2008, 43, 1926-1944.	2.6	23
44	Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorganic and Medicinal Chemistry, 2008, 16, 4954-4962.	1.4	16
45	Bis-tetrahydroisoquinoline derivatives: AG525E1, a new step in the search for non-quaternary non-peptidic small conductance Ca2+-activated K+ channel blockers. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3440-3445.	1.0	14
46	Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochemical Pharmacology, 2008, 76, 404-415.	2.0	53
47	740 Development of a New Optimized 5-ASA Molecule Ged-0507-34 with Intestinal Anti-Inflammatory and Analgesic Properties. Gastroenterology, 2008, 134, A-106-A-107.	0.6	1
48	Molecular modelling of phthalates – PPARs interactions. Journal of Enzyme Inhibition and Medicinal Chemistry, 2008, 23, 611-616.	2.5	25
49	Synthesis and Radioligand Binding Studies of Bis-isoquinolinium Derivatives as Small Conductance Ca ²⁺ -Activated K ⁺ Channel Blockers. Journal of Medicinal Chemistry, 2007, 50, 5070-5075.	2.9	27
50	Quantitative structure-activity relationships studies of antioxidant hexahydropyridoindoles and flavonoid derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2007, 22, 556-562.	2.5	12
51	Three-Dimensional Quantitative Structure–Activity Relationship ofMT3 Melatonin Binding Site Ligands: A Comparative Molecular Field Analysis. QSAR and Combinatorial Science, 2007, 26, 820-827.	1.5	3
52	Differences in Binding Sites of Two Melatonin Receptors Help to Explain Their Selectivity to Some Melatonin Analogs: A Molecular Modeling Study. Journal of Biomolecular Structure and Dynamics, 2006, 24, 91-107.	2.0	16
53	Novel 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New CB2Cannabinoid Receptors Agonists:Â Synthesis, Pharmacological Properties and Molecular Modeling. Journal of Medicinal Chemistry, 2006, 49, 70-79.	2.9	81
54	Solid-phase synthesis andÂpharmacological evaluation ofÂaÂlibrary ofÂpeptidomimetics asÂpotential farnesyltransferase inhibitors: anÂapproach toÂnew lead compounds. European Journal of Medicinal Chemistry, 2006, 41, 745-755.	2.6	16

#	Article	IF	CITATIONS
55	Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARÎ ³ agonists. Bioorganic and Medicinal Chemistry, 2006, 14, 7377-7391.	1.4	18
56	A Computational View of COX-2 Inhibition. Anti-Cancer Agents in Medicinal Chemistry, 2006, 6, 239-249.	0.9	1
57	PPARÂ as a new therapeutic target in inflammatory bowel diseases. Gut, 2006, 55, 1341-1349.	6.1	363
58	Homology modelling of the serotoninergic 5-HT2c receptor. Journal of Enzyme Inhibition and Medicinal Chemistry, 2006, 21, 285-292.	2.5	10
59	Molecular Modeling of Human MT1 and MT2 Melatonin Receptors. , 2006, , 259-270.		0
60	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-l³. Journal of Experimental Medicine, 2005, 201, 1205-1215.	4.2	428
61	Lipid-lowering properties of 6-benzoyl-2(3H)-benzothiazolone and structurally related compounds. Journal of Enzyme Inhibition and Medicinal Chemistry, 2005, 20, 525-532.	2.5	7
62	Novel Benzopyridothiadiazepines as Potential Active Antitumor Agents. Journal of Medicinal Chemistry, 2005, 48, 7363-7373.	2.9	76
63	Identification of a pharmacophore of SKCa channel blockers. Journal of Enzyme Inhibition and Medicinal Chemistry, 2005, 20, 517-523.	2.5	19
64	2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database ChemInform, 2004, 35, no.	0.1	0
65	Potent and Selective Farnesyl Transferase Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 6812-6820.	2.9	22
66	Docking Study of Ligands into the Colchicine Binding Site of Tubulin. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 541-547.	2.5	36
67	2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database. Journal of Chemical Information and Computer Sciences, 2004, 44, 276-285.	2.8	81
68	Design and Synthesis of Naphthalenic Dimers as Selective MT1Melatoninergic Ligands. Journal of Medicinal Chemistry, 2003, 46, 1127-1129.	2.9	61
69	Design, Synthesis and In Vitro Evaluation of Novel Benzo[b]thiophene Derivatives as Serotonin N-acetyltransferase (AANAT) Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 119-125.	2.5	10
70	Design, Synthesis and In Vitro Evaluation of Novel Derivatives as Serotonin N -Acetyltransferase Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 409-414.	2.5	13
71	Design, Synthesis, and Pharmacological Evaluation of New Farnesyl Protein Transferase Inhibitors. Journal of Medicinal Chemistry, 2002, 45, 533-536.	2.9	20
72	Synthesis and Structureâ ``Affinityâ ``Activity Relationships of Novel Benzofuran Derivatives as MT2 Melatonin Receptor Selective Ligands. Journal of Medicinal Chemistry, 2002, 45, 2788-2800.	2.9	88

#	Article	IF	CITATIONS
73	Investigations of new lead structures for the design of novel cyclooxygenase-2 inhibitors. European Journal of Medicinal Chemistry, 2002, 37, 461-468.	2.6	45
74	Three-Dimensional Quantitative Structureâ´'Activity Relationships of Cyclo-oxygenase-2 (COX-2) Inhibitors: A Comparative Molecular Field Analysis. Journal of Medicinal Chemistry, 2001, 44, 3223-3230.	2.9	105
75	Conformation of the tripeptide Cbz-Pro-Leu-Trp-OBzl(CF3)2deduced from two-dimensional1H-NMR and conformational energy calculations is related to its affinity for NK1-receptor. Journal of Peptide Science, 2001, 7, 323-330.	0.8	10
76	Three-Dimensional Quantitative Structure-Activity Relationship of Arylalkylamine N-acetyltransferase (AANAT) Inhibitors: A Comparative Molecular Field Analysis. QSAR and Combinatorial Science, 2001, 20, 414-421.	1.4	1
77	Comparative Molecular Field Analysis of Selective Cyclooxygenase-2 (COX-2) Inhibitors. QSAR and Combinatorial Science, 2000, 19, 127-134.	1.4	25
78	Synthesis and preliminary pharmacological results on new naphthalene derivatives as 5-HT4 receptor ligands. European Journal of Medicinal Chemistry, 2000, 35, 699-706.	2.6	16
79	Critical Role of Tyrosine 277 in the Ligand-Binding and Transactivating Properties of Retinoic Acid Receptor αâ€. Biochemistry, 2000, 39, 2183-2192.	1.2	10
80	Title is missing!. International Journal of Peptide Research and Therapeutics, 1999, 6, 221-233.	0.1	3
81	Synthesis and biological evaluation of conformationally restricted derivatives of tryptophan as NK1/NK2 ligands. International Journal of Peptide Research and Therapeutics, 1999, 6, 221-233.	0.1	6
82	Pharmacophoric Search and 3D-QSAR Comparative Molecular Field Analysis Studies on Agonists of Melatonin Sheep Receptors. Journal of Medicinal Chemistry, 1998, 41, 4453-4465.	2.9	43
83	Conformational investigations of two diastereoisomers of the tripeptide N?-Z-N?-Bz-Lys-Ala-Sar-OBzl. 1. Molecular dynamics simulations using the AMBER and the SPASIBA force fields. , 1997, 2, 195-205.		1
84	Conformational investigations of two diastereoisomers of the tripeptide N?-Z-N?-Bz-Lys-Ala-Sar-OBzl. 2. Infrared and Raman studies and normal modes analysis. , 1997, 2, 206-214.		0